Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial
Yuanyuan Zhao, Gang Chen, Xingya Li, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101470-101470
Open Access | Times Cited: 15

Showing 15 citing articles:

Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
Emily Wolf, Guilherme Sacchi de Camargo Correia, Shenduo Li, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 128-128
Open Access | Times Cited: 1
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Nicolas Roussot, Courèche Kaderbhaï, François Ghiringhelli
Cancers (2025) Vol. 17, Iss. 5, pp. 906-906
Open Access | Times Cited: 1
Antibodies to watch in 2025
Silvia Crescioli, Hélène Kaplon, Lin Wang, et al.
mAbs (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Preclinical insights into the potential of itaconate and its derivatives for liver disease therapy
Xiaodong Wu, Yanhong Song, Zhengwei Yuan, et al.
Metabolism (2025), pp. 156152-156152
Closed Access
Leveraging HER2-targeted Biparatopic Antibodies in Solid Tumors
Xinlin Liu, Xinyi Fan, Xiang Gao, et al.
Pharmacological Research (2025) Vol. 214, pp. 107687-107687
Open Access
Bispecific antibodies (bsAbs) directed against PD-1/PD-L1 and CTLA-4; a mini review
Amirhossein Mardi, Leili Aghebati‐Maleki
Human Antibodies (2025)
Closed Access
Recent advances in therapeutic strategies for non-small cell lung cancer
Po‐Lan Su, Naoki Furuya, Atif Asrar, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment
Saqib Raza Khan, Daniel Breadner
Current Oncology (2025) Vol. 32, Iss. 4, pp. 206-206
Open Access
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Lorenzo Guidi, Julian Etessami, Carmine Valenza, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
VISTA: A promising target for overcoming immune evasion in gynecologic cancers
Sicong Liu, Feng Ji, Yue Ding, et al.
International Immunopharmacology (2024) Vol. 138, pp. 112655-112655
Closed Access | Times Cited: 3
Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials
Yiqian Liu, Liyun Miao, Xiao Chen, et al.
Medicine (2024) Vol. 103, Iss. 27, pp. e38459-e38459
Open Access | Times Cited: 1
Advances in the Management of Lung Cancer Brain Metastases
Kathryn Hockemeyer, Chad G. Rusthoven, Luke Pike
Cancers (2024) Vol. 16, Iss. 22, pp. 3780-3780
Open Access | Times Cited: 1
Immune Checkpoint Inhibitors in Cancer Immunotherapy
Fathima Hasnain Nadeem Hussain, Afsheen Raza
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 123-156
Closed Access
Blood and blood treatments
K. Dean Gubler, Madelyne H. Stroz, Masen Putnam, et al.
Side effects of drugs annual (2024), pp. 365-376
Closed Access
Next-generation immunotherapy: igniting new hope for lung cancer
Molly Li, Antony C. S. Chan, Kevin Mok, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Page 1

Scroll to top